ArticleInternational journal of clinical and experimental pathology2018
Reduced expression of SCUBE2 predicts poor prognosis in gastric cancer patients.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 6 citations in OpenAlex.
- Clinical Significance of Tumor Invasion Gene Profiling in Early-Stage Hormone Receptor-Positive Breast Cancer: A Cross-Sectional Study.Health science reports · 2026Article
- The biology of SCUBE.Journal of biomedical science · 2023Review
- The Multifaceted Role of Signal Peptide-CUB-EGF Domain-Containing Protein (SCUBE) in Cancer.International journal of molecular sciences · 2022Review
- A 3-gene biomarker signature to predict response to taxane-based neoadjuvant chemotherapy in breast cancer.PloS one · 2020Article
- Circular RNA circ_SETD2 represses breast cancer progression via modulating the miR-155-5p/SCUBE2 axis.Open medicine (Warsaw, Poland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Signal peptide-CUB-EGF (epidermal growth factor) domain-containing protein 2 (SCUBE2) is a secreted cell-surface glycoprotein. Decreased SCUBE2 expression has been reported in a variety of human cancers, including breast cancer, but its role in gastric cancer (GC) is still unknown. The present study was designed to evaluate the role of SCUBE2 expression in the prognosis of GC patients. SCUBE2 expression in GC tissues was detected by quantitative real-time reverse transcription polymerase chain reaction, Western blotting, and immunohistochemistry. The association between SCUBE2 expression and clinicopathological characteristics was evaluated using the Chi-square test. The Kaplan-Meier method and Cox proportional hazards models were applied to estimate the effect of SCUBE2 expression on survival. Our results show that expression of SCUBE2 in GC tissues is significantly lower than that in adjacent normal gastric mucosa tissues. Loss of SCUBE2 expression was associated with larger tumors (
Indexed as
Identifiers
31938191PMC6958003W3027739545What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.